BACKGROUND AND AIMS: Early detection of perihilar cholangiocarcinoma (CCA) among patients with primary sclerosing cholangitis (PSC) is important to identify more people eligible for curative therapy. While many recommend CCA screening, there are divergent opinions and limited data regarding the use of ultrasound or magnetic resonance imaging (MRI) for early CCA detection, and it is unknown whether there is benefit in testing asymptomatic individuals. Our aims were to assess the diagnostic performances and prognostic implications of ultrasound and MRI-based CCA detection. APPROACH AND RESULTS: This is a multicenter review of 266 adults with PSC (CCA, n = 120) who underwent both an ultrasound and MRI within 3 months. Images were re-examined by radiologists who were blinded to the clinical information. Respectively, MRI had a higher area under the curve compared with ultrasound for CCA detection: 0.87 versus 0.70 for the entire cohort; 0.81 versus 0.59 for asymptomatic individuals; and 0.88 versus 0.71 for those listed for CCA transplant protocol. The absence of symptoms at CCA diagnosis was associated with improved 5-year outcomes including overall survival (82% vs. 46%, log-rank P < 0.01) and recurrence-free survival following liver transplant (89% vs. 65%, log-rank P = 0.04). Among those with asymptomatic CCA, MRI detection (compared with ultrasound) was associated with reduction in both mortality (hazard ratio, 0.10; 95% confidence interval, 0.01-0.96) and CCA progression after transplant listing (hazard ratio, 0.10; 95% confidence interval, 0.01-0.90). These benefits continued among patients who had annual monitoring and PSC for more than 1 year before CCA was diagnosed. CONCLUSIONS: MRI is superior to ultrasound for the detection of early-stage CCA in patients with PSC. Identification of CCA before the onset of symptoms with MRI is associated with improved outcomes.
BACKGROUND AND AIMS: Early detection of perihilar cholangiocarcinoma (CCA) among patients with primary sclerosing cholangitis (PSC) is important to identify more people eligible for curative therapy. While many recommend CCA screening, there are divergent opinions and limited data regarding the use of ultrasound or magnetic resonance imaging (MRI) for early CCA detection, and it is unknown whether there is benefit in testing asymptomatic individuals. Our aims were to assess the diagnostic performances and prognostic implications of ultrasound and MRI-based CCA detection. APPROACH AND RESULTS: This is a multicenter review of 266 adults with PSC (CCA, n = 120) who underwent both an ultrasound and MRI within 3 months. Images were re-examined by radiologists who were blinded to the clinical information. Respectively, MRI had a higher area under the curve compared with ultrasound for CCA detection: 0.87 versus 0.70 for the entire cohort; 0.81 versus 0.59 for asymptomatic individuals; and 0.88 versus 0.71 for those listed for CCA transplant protocol. The absence of symptoms at CCA diagnosis was associated with improved 5-year outcomes including overall survival (82% vs. 46%, log-rank P < 0.01) and recurrence-free survival following liver transplant (89% vs. 65%, log-rank P = 0.04). Among those with asymptomatic CCA, MRI detection (compared with ultrasound) was associated with reduction in both mortality (hazard ratio, 0.10; 95% confidence interval, 0.01-0.96) and CCA progression after transplant listing (hazard ratio, 0.10; 95% confidence interval, 0.01-0.90). These benefits continued among patients who had annual monitoring and PSC for more than 1 year before CCA was diagnosed. CONCLUSIONS: MRI is superior to ultrasound for the detection of early-stage CCA in patients with PSC. Identification of CCA before the onset of symptoms with MRI is associated with improved outcomes.
Authors: Roger Chapman; Johan Fevery; Anthony Kalloo; David M Nagorney; Kirsten Muri Boberg; Benjamin Shneider; Gregory J Gores Journal: Hepatology Date: 2010-02 Impact factor: 17.425
Authors: Roman Zenouzi; Christopher L Welle; Sudhakar K Venkatesh; Christoph Schramm; John E Eaton Journal: Semin Liver Dis Date: 2019-04-30 Impact factor: 6.115
Authors: Sarwa Darwish Murad; W Ray Kim; Terry Therneau; Gregory J Gores; Charles B Rosen; James A Martenson; Steven R Alberts; Julie K Heimbach Journal: Hepatology Date: 2012-07-17 Impact factor: 17.425
Authors: John E Eaton; Jayant A Talwalkar; Konstantinos N Lazaridis; Gregory J Gores; Keith D Lindor Journal: Gastroenterology Date: 2013-07-01 Impact factor: 22.682
Authors: Ahmad Hassan Ali; James H Tabibian; Navine Nasser-Ghodsi; Ryan J Lennon; Thomas DeLeon; Mitesh J Borad; Moira Hilscher; Marina G Silveira; Elizabeth J Carey; Keith D Lindor Journal: Hepatology Date: 2018-04-19 Impact factor: 17.425
Authors: Matthew A Morgan; Rachita Khot; Karthik M Sundaram; Daniel R Ludwig; Rashmi T Nair; Pardeep K Mittal; Dhakshina M Ganeshan; Sudhakar K Venkatesh Journal: Abdom Radiol (NY) Date: 2022-09-05
Authors: Ju Dong Yang; Hassan Ghoz; Mohammed M Aboelsoud; William R Taylor; Tracy C Yab; Calise K Berger; Xiaoming Cao; Patrick H Foote; Nasra H Giama; Emily G Barr Fritcher; Douglas W Mahoney; Catherine D Moser; Thomas C Smyrk; Benjamin R Kipp; Gregory J Gores; Lewis R Roberts; John B Kisiel Journal: Hepatol Commun Date: 2021-05-03
Authors: Hege Marie Vedeld; Marit M Grimsrud; Kim Andresen; Heidi D Pharo; Erik von Seth; Tom H Karlsen; Hilde Honne; Vemund Paulsen; Martti A Färkkilä; Annika Bergquist; Marine Jeanmougin; Lars Aabakken; Kirsten M Boberg; Trine Folseraas; Guro E Lind Journal: Hepatology Date: 2021-12-05 Impact factor: 17.298